Bajaj HealthCare Limited (BAJAJHCARE.NS)
INR 569.3
(-4.08%)
INR 569.3
(-4.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.86 Billion INR | -8.81% |
| 2022 | 5.33 Billion INR | 35.95% |
| 2021 | 3.92 Billion INR | 46.93% |
| 2020 | 2.67 Billion INR | 53.45% |
| 2019 | 1.74 Billion INR | 26.42% |
| 2018 | 1.37 Billion INR | -10.86% |
| 2017 | 1.54 Billion INR | 28.51% |
| 2016 | 1.2 Billion INR | -0.12% |
| 2015 | 1.2 Billion INR | 12.75% |
| 2014 | 1.06 Billion INR | -6.22% |
| 2013 | 1.13 Billion INR | 12.27% |
| 2012 | 1.01 Billion INR | 11.64% |
| 2011 | 908.41 Million INR | 23.55% |
| 2010 | 735.24 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -2.78 Billion INR | -157.19% |
| 2023 Q4 | 4.86 Billion INR | 0.0% |
| 2023 FY | 4.86 Billion INR | -8.81% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 5.21 Billion INR | 0.0% |
| 2022 Q2 | 4.68 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 5.33 Billion INR | 35.95% |
| 2022 Q4 | 5.33 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 3.92 Billion INR | 46.93% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 3.61 Billion INR | 0.0% |
| 2021 Q4 | 3.92 Billion INR | 0.0% |
| 2020 Q2 | 2.14 Billion INR | 0.0% |
| 2020 Q4 | 2.67 Billion INR | 0.0% |
| 2020 FY | 2.67 Billion INR | 53.45% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 1.44 Billion INR | 0.0% |
| 2019 FY | 1.74 Billion INR | 26.42% |
| 2019 Q4 | 1.74 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q4 | 1.29 Billion INR | -5.71% |
| 2018 Q2 | 1.57 Billion INR | 0.0% |
| 2018 Q3 | 1.37 Billion INR | -12.37% |
| 2018 FY | 1.37 Billion INR | -10.86% |
| 2018 Q1 | 1.57 Billion INR | 1.72% |
| 2017 Q1 | 1.4 Billion INR | 17.02% |
| 2017 Q2 | 1.4 Billion INR | 0.0% |
| 2017 Q3 | 1.54 Billion INR | 9.81% |
| 2017 Q4 | 1.54 Billion INR | 0.0% |
| 2017 FY | 1.54 Billion INR | 28.51% |
| 2016 Q3 | 1.2 Billion INR | -1.11% |
| 2016 Q2 | 1.21 Billion INR | 0.0% |
| 2016 Q4 | 1.2 Billion INR | 0.0% |
| 2016 FY | 1.2 Billion INR | -0.12% |
| 2016 Q1 | 1.21 Billion INR | 0.99% |
| 2015 Q2 | 1.2 Billion INR | 0.0% |
| 2015 Q4 | 1.2 Billion INR | 2.97% |
| 2015 Q3 | 1.16 Billion INR | -3.26% |
| 2015 Q1 | 1.2 Billion INR | 0.0% |
| 2015 FY | 1.2 Billion INR | 12.75% |
| 2014 FY | 1.06 Billion INR | -6.22% |
| 2013 FY | 1.13 Billion INR | 12.27% |
| 2012 FY | 1.01 Billion INR | 11.64% |
| 2011 FY | 908.41 Million INR | 23.55% |
| 2010 FY | 735.24 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 70.089% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -646.256% |
| FDC Limited | 3.7 Billion INR | -31.232% |
| Gufic Biosciences Limited | 5.59 Billion INR | 13.074% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 92.056% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 56.609% |
| Orchid Pharma Limited | 3.84 Billion INR | -26.628% |
| Alkem Laboratories Limited | 48.6 Billion INR | 89.985% |
| Brooks Laboratories Limited | 248.6 Million INR | -1858.024% |
| Eris Lifesciences Limited | 38.26 Billion INR | 87.28% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 6.046% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 65.457% |
| Innova Captab Limited | 4.89 Billion INR | 0.657% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1540.271% |
| Wanbury Limited | 3.15 Billion INR | -54.259% |
| Lupin Limited | 96.23 Billion INR | 94.942% |
| Aarti Drugs Limited | 11.5 Billion INR | 57.687% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 41.003% |
| Albert David Limited | 1.15 Billion INR | -323.237% |
| Alembic Limited | 1.43 Billion INR | -239.897% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1585.486% |
| Hester Biosciences Limited | 3.59 Billion INR | -35.412% |
| Hikal Limited | 12.99 Billion INR | 62.542% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -112.612% |
| Ind-Swift Limited | 13.45 Billion INR | 63.817% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 23.088% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -655.986% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -352.998% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -146.301% |
| Medico Remedies Limited | 438.24 Million INR | -1010.721% |
| Morepen Laboratories Limited | 4.45 Billion INR | -9.146% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -90.054% |
| RPG Life Sciences Limited | 1.38 Billion INR | -252.678% |
| Sigachi Industries Limited | 2.53 Billion INR | -92.302% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 97.348% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -139.288% |
| Themis Medicare Limited | 1.88 Billion INR | -157.888% |
| Unichem Laboratories Limited | 8.06 Billion INR | 39.676% |
| Vaishali Pharma Limited | 371.16 Million INR | -1211.464% |
| Venus Remedies Limited | 1.39 Billion INR | -249.488% |
| Windlas Biotech Limited | 1.76 Billion INR | -176.148% |
| ZIM Laboratories Limited | 2.08 Billion INR | -133.937% |
| Sakar Healthcare Limited | 1.26 Billion INR | -285.32% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 96.802% |
| Divi's Laboratories Limited | 18.99 Billion INR | 74.367% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -32.956% |
| Mankind Pharma Limited | 23.87 Billion INR | 79.612% |
| Sequent Scientific Limited | 8.27 Billion INR | 41.171% |
| Laurus Labs Limited | 42.71 Billion INR | 88.604% |
| Neuland Laboratories Limited | 5.49 Billion INR | 11.474% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 54.542% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 92.524% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 93.22% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -521.015% |
| Wockhardt Limited | 39.87 Billion INR | 87.791% |
| Bal Pharma Limited | 2.51 Billion INR | -93.832% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 95.449% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -130.821% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -2946.272% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -38.854% |
| Shilpa Medicare Limited | 12.93 Billion INR | 62.361% |
| Valiant Laboratories Limited | 1.05 Billion INR | -359.969% |
| Ajanta Pharma Limited | 10.71 Billion INR | 54.552% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -182.644% |
| Granules India Limited | 22.95 Billion INR | 78.794% |
| Medicamen Biotech Limited | 940.36 Million INR | -417.635% |
| Ipca Laboratories Limited | 33.74 Billion INR | 85.574% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -317.75% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.132% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 94.067% |
| NATCO Pharma Limited | 10.53 Billion INR | 53.782% |
| Suven Life Sciences Limited | 148.62 Million INR | -3175.222% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -63.679% |
| Strides Pharma Science Limited | 37.68 Billion INR | 87.082% |
| Indoco Remedies Limited | 10.34 Billion INR | 52.934% |
| Alpa Laboratories Limited | 307.12 Million INR | -1484.93% |
| Lasa Supergenerics Limited | 541.92 Million INR | -798.218% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -25.04% |